Business Summary
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Company Officers
Mr. Christopher A. Viehbacher
Mr. Christopher A. Viehbacher
Mr. Michael R. McDonnell
President, Chief Executive Officer & Director
President, Chief Executive Officer & Director
Chief Financial Officer & Executive Vice President
Mr. Michael E. Dambach
Dr. Jane Grogan
Ms. Nicole Murphy
Ms. Nicole Murphy
Ms. Caroline D. Dorsa
Dr. Eric K. Rowinsky
Dr. Eric K. Rowinsky
Dr. Stephen A. Sherwin
Dr. Stephen A. Sherwin
Mr. Monish Patolawala
Mr. Monish Patolawala
Mr. Christopher A. Viehbacher
Ms. Susan Langer
Mr. William A. Hawkins
Mr. Jesus B. Mantas
Mr. Jesus B. Mantas
Dr. Maria C. Freire
Dr. Maria C. Freire
Ms. Caroline D. Dorsa
Mr. William A. Hawkins
Ms. Susan Langer
Mr. Wendell C. Taylor
Treasurer & Vice President
Executive Vice President & Head-Research
Head-Pharmaceutical Operations & Technology
Head-Pharmaceutical Operations & Technology
Chairman
Independent Director
Independent Director
Independent Director
Independent Director
Independent Director
Independent Director
President, Chief Executive Officer & Director
Independent Director
Independent Director
Independent Director
Independent Director
Independent Director
Independent Director
Chairman
Independent Director
Independent Director
Secretary
Revenue, Returns and Ratios
Total Revenue - TTM
Ratios
Revenue Summary - TTM
Return on Equity vs. Return on Assets